SPOTLIGHT -
Rizwan Nurani, MD, an expert on prostate cancer, describes the role of balloon spacers in the treatment space.
FDA grants 510(k) clearance to AI companion tool for TULSA-PRO system
The Contouring Assistant now marks Profound Medical’s second FDA-cleared TULSA-AI module.
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
TRANSFORM trial to evaluate screening methods in prostate cancer
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Study progresses of NK cell therapy in mCRPC
All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study to the second dose level of INKmune.
Dr. Tosoian on screening approaches and tools for prostate cancer
"I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are only going to get better," says Jeffrey Tosoian, MD, MPH.